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Abstract
Background
Maternal smoking during pregnancy is an established risk factor for low infant birth weight,
but evidence on critical exposure windows and timing of fetal growth restriction is limited.
Here we investigate the associations of maternal quitting, reducing, and continuing smoking
during pregnancy with longitudinal fetal growth by triangulating evidence from 3 analytical
approaches to strengthen causal inference.
Methods and findings
We analysed data from 8,621 European liveborn singletons in 2 population-based preg-
nancy cohorts (the Generation R Study, the Netherlands 2002–2006 [n = 4,682]) and the
Born in Bradford study, United Kingdom 2007–2010 [n = 3,939]) with fetal ultrasound and
birth anthropometric measures, parental smoking during pregnancy, and maternal genetic
data. Associations with trajectories of estimated fetal weight (EFW) and individual fetal
parameters (head circumference, femur length [FL], and abdominal circumference [AC])
from 12–16 to 40 weeks’ gestation were analysed using multilevel fractional polynomial
models. We compared results from (1) confounder-adjusted multivariable analyses, (2) a
Mendelian randomization (MR) analysis using maternal rs1051730 genotype as an instru-
ment for smoking quantity and ease of quitting, and (3) a negative control analysis compar-
ing maternal and mother’s partner’s smoking associations. In multivariable analyses,
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women who continued smoking during pregnancy had a smaller fetal size than non-smokers
from early gestation (16–20 weeks) through to birth (p-value for each parameter < 0.001).
Fetal size reductions in continuing smokers followed a dose-dependent pattern (compared
to non-smokers, difference in mean EFW [95% CI] at 40 weeks’ gestation was −144 g [−182
to −106], −215 g [−248 to −182], and −290 g [−334 to −247] for light, moderate, and heavy
smoking, respectively). Overall, fetal size reductions were most pronounced for FL. The
fetal growth trajectory in women who quit smoking in early pregnancy was similar to that of
non-smokers, except for a shorter FL and greater AC around 36–40 weeks’ gestation. In
MR analyses, each genetically determined 1-cigarette-per-day increase was associated
with a smaller EFW from 20 weeks’ gestation to birth in smokers (p = 0.01, difference in
mean EFW at 40 weeks = −45 g [95% CI −81 to −10]) and a greater EFW from 32 weeks’
gestation onwards in non-smokers (p = 0.03, difference in mean EFW at 40 weeks = 26 g
[95% CI 5 to 47]). There was no evidence that partner smoking was associated with fetal
growth. Study limitations include measurement error due to maternal self-report of smoking
and the modest sample size for MR analyses resulting in unconfounded estimates being
less precise. The apparent positive association of the genetic instrument with fetal growth in
non-smokers suggests that genetic pleiotropy may have masked a stronger association in
smokers.
Conclusions
A consistent linear dose-dependent association of maternal smoking with fetal growth was
observed from the early second trimester onwards, while no major growth deficit was found
in women who quit smoking early in pregnancy except for a shorter FL during late gestation.
These findings reinforce the importance of smoking cessation advice in preconception and
antenatal care and show that smoking reduction can lower the risk of impaired fetal growth
in women who struggle to quit.
Author summary
Why was this study done?
• Maternal smoking during pregnancy is an established risk factor for low infant birth
weight. Understanding when and which parameters of fetal growth are affected by dif-
ferent smoking behaviours is important for strengthening and focusing clinical and
public health guidelines.
• The importance of smoking cessation in early pregnancy and the extent to which fetal
growth restriction can be prevented or minimised by lowering cigarette consumption in
women who find quitting difficult is also uncertain.
What did the researchers do and find?
• We analysed data from 8,621 white European liveborn singletons from 2 population-
based pregnancy cohorts to assess the associations of maternal quitting, reducing, and
continuing smoking during pregnancy with the longitudinal growth of different fetal
Maternal smoking during pregnancy and fetal growth
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studies with different data publishing policies. The
individual-level data are not available through a
public repository due to ethical and legal
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collaboration policy and the datasets generated and
analysed for this study are available upon request.
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local rules and regulations.
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We compared results across 3 different analytical approaches (conventional multivari-
able, Mendelian randomization, and parental negative control analyses) to strengthen
confidence in our findings.
• We found that pre-pregnancy smokers who continued smoking during pregnancy had
a reduced fetal size from early gestation (12–16 weeks) onwards. Associations of mater-
nal smoking with each fetal parameter followed a dose-dependent pattern, with fetal
size reductions increasing in magnitude with the number of cigarettes smoked.
• While all fetal parameters were affected in women who continued smoking during preg-
nancy, size reductions were most pronounced for femur length. In pre-pregnancy
smokers who gave up smoking early in pregnancy, no overall growth deficit was
observed, except for a smaller femur length towards the end of pregnancy.
• The association of maternal smoking with reduced fetal growth was consistent across all
3 methods, thus providing stronger support that the association is causal, in comparison
to current evidence, which relies solely on multivariable regression.
What do these findings mean?
• Our findings reinforce existing advice promoting and supporting smoking cessation in
preconception and antenatal care services; they provide strong support for these
recommendations.
• The consistent results across methods for a linear dose-dependent association of mater-
nal smoking with reduced fetal growth from early gestation in women who continue
smoking during pregnancy provide evidence to support reducing smoking amounts in
those who struggle to quit.
Introduction
Maternal smoking during pregnancy is one of the most important modifiable determinants of
low infant birth weight and other adverse perinatal outcomes [1]. Whilst the prevalence of
pregnancy smoking has declined, it remains high in the US and Western Europe, where
approximately 15%–20% of all pregnant women smoke [2]. According to the US Surgeon Gen-
eral’s reports [3,4], there is substantial evidence supporting a direct link between pregnancy
smoking and low infant birth weight, with this evidence being consistent across a multitude of
studies using conventional multivariable analyses of observational data. However, these results
from conventional observational approaches may be explained by residual confounding given
that women who smoke during pregnancy are more likely to be socioeconomically disadvan-
taged and to engage in other risky health behaviours that may lead to low birth weight. More
recent findings from quasi- experimental studies comparing populations with different
tobacco control policies [5–7], and from observational studies using Mendelian randomization
(MR) [8], parental negative control [9], and discordant sibling [10] designs, support an intra-
uterine effect of maternal smoking during pregnancy on infant birth weight.
Maternal smoking during pregnancy and fetal growth
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Still, evidence on the critical smoking exposure window and timing of smoking-related
fetal growth restriction is limited. Previous studies have mainly focused on size at birth only,
with few studies exploring when during pregnancy smoking starts to affect growth, or whether
there are differences in its effect on different fetal growth parameters. Pregnancy smoking has
been associated with a reduction in first trimester crown–rump length (CRL) [11], but studies
using repeat ultrasound measures have failed to identify an association with early second tri-
mester fetal size, and the magnitude of reported associations with different fetal parameters
later in pregnancy varies considerably [12]. This inconsistency largely reflects between-study
heterogeneity in longitudinal fetal growth assessment and adjustment for confounding factors,
which hamper the ability to determine causal intrauterine effects from early fetal life [12].
There is also uncertainty about the impact of smoking cessation in early pregnancy and the
extent to which fetal growth restriction can be prevented or minimised by lowering cigarette
consumption. Obtaining stronger causal evidence of when in pregnancy smoking influences
fetal growth, how quitting affects this, and whether there is a dose response in those who con-
tinue smoking will provide stronger evidence to inform updated guidelines and to help
women make more informed decisions. Furthermore, understanding whether smoking
reduces birth weight by universally reducing growth across all growth parameters or has vary-
ing effects could provide insights into the mechanisms through which smoking affects fetal
growth.
The aim of this study was to determine the associations of maternal quitting, reducing, and
continuing smoking during pregnancy with longitudinal trajectories of different fetal growth
parameters (head circumference [HC], femur length [FL], abdominal circumference [AC],
and estimated fetal weight [EFW]) in a joint analysis of data from 2 population-based preg-
nancy cohorts. To improve causal inference, we triangulated findings from 3 approaches with
differing sources of bias (multivariable regression, MR, and parental negative control) [13].
This study provides novel insights into the impact of quitting or reducing smoking during
pregnancy on fetal growth that can be used to tailor advice and support to individual women.
Methods
Cohorts
We identified cohorts from the MR-PREG consortia, a collaboration of cohorts used to explore
causes and consequences of different pregnancy complications and outcomes. To contribute
to this study, cohorts had to have repeat fetal ultrasound scan measurements. We used parental
and offspring data from the Generation R Study (GenR) [14] and the Born in Bradford study
(BiB) [15], 2 population-based pregnancy cohorts including participants from multi-ethnic
urban populations (see S1 Text for a detailed description of both cohorts). GenR is based in
Rotterdam (the Netherlands) and consists of 9,778 women (response rate at baseline = 61%)
who had an expected delivery date between April 2002 and January 2006. Most participants
(n = 8,880, 91%) were recruited during pregnancy. BiB enrolled 12,450 women residing in
Bradford (response rate> 80%), a city in the north of England. Women participating in BiB
had an expected delivery date between March 2007 and December 2010 and were mainly
recruited at their oral glucose tolerance test (OGTT) appointment at 26–28 weeks’ gestation
(all pregnant women booked to deliver in Bradford are offered an OGTT). For the present
analysis, we included women who gave birth to singletons without known fetal/birth congeni-
tal anomalies and with fetal growth and maternal smoking data (see S1 Fig). We further
restricted analyses to participants of white European origin, as smoking behaviours and fetal
growth trajectories differ considerably by ethnicity, and for other ethnic groups, numbers were
too small for reliable estimates. This resulted in a study population of 8,621 liveborn singletons
Maternal smoking during pregnancy and fetal growth
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(GenR, n = 4,682; BiB, n = 3,939). Of these, 6,527 had maternal genotype data (GenR,
n = 3,604; BiB, n = 2,923) and were included in the MR analyses, and 5,537 had partner smok-
ing data (GenR, n = 4,206; BiB, n = 1,331) for inclusion in the negative control study.
All study participants gave written informed consent, and the study was approved by the
local medical ethical committees (GenR: MEC 198.782/2001/31; BiB: ref 06/Q1202/48).
Parental smoking
Full details of how parental smoking was assessed are provided in S1 Text. Based on the avail-
able data in both cohorts, maternal smoking during pregnancy was categorised as follows: (1)
non-smokers (i.e., women who had never smoked or stopped smoking several months [>6
months in GenR and>3 months in BiB] prior to pregnancy); (2) pre-pregnancy smokers who
quit in early pregnancy (i.e., women who reported smoking in the months before becoming
pregnant but not after the first trimester); and (3) pre-pregnancy smokers who continued
smoking through pregnancy (i.e., women who reported smoking in the months before becom-
ing pregnant, in the first trimester, and during mid and/or late pregnancy).
We also extracted information on the number of cigarettes smoked by women who contin-
ued to smoke through pregnancy. This was done by taking the mean of the smoking quantity
reported during the first trimester and during mid and/or late pregnancy. Since each cohort
used different cutoffs to categorise self-reported smoking quantity (intensity), these data were
grouped into ‘light’ (1–4 [GenR] or 1–5 [BiB] cigarettes per day), ‘moderate’ (5–9 [GenR] or
6–10 [BiB] cigarettes per day), and ‘heavy’ smoking (�10 [GenR] or >10 [BiB] cigarettes per
day).
To strengthen causal inference, we used information on partner smoking during pregnancy
as a negative control [13,16]. Under the assumption that confounding would be similar for
maternal and partner smoking, stronger estimates for the association of fetal growth parame-
ters with maternal than partner smoking can be interpreted as support for a causal intrauterine
effect of maternal smoking, while similar effect estimates would be suggestive of unmeasured
shared familial confounding [13]. We used the same categories of partner smoking quantity
(light, moderate, and heavy smoking) to those used for maternal smoking.
Instrument selection and genotyping for MR
We selected the rs1051730 single nuclear polymorphism (SNP) in the α-nicotinic acetylcholine
receptor (CHRNA3/5) gene cluster as an instrumental variable for our MR analysis because
this variant has been shown to robustly (in genome-wide discovery and replication studies
[17,18]) relate to smoking intensity and ease of quitting, and also to relate to these smoking
traits in pregnancy [19]. Full details of genotyping and quality control are provided in S1 Text
and S1 Table.
Fetal growth assessment
Longitudinal fetal growth trajectory analyses were based on repeat fetal ultrasound and birth
anthropometric measurements starting at 12–16 weeks’ gestation and ending at term. The col-
lection of fetal ultrasound data in both cohorts has been described in detail elsewhere [20,21];
see also S1 Text for study-specific procedures including numbers of anthropometric measure-
ments collected. In GenR and BiB, gestational age was determined using CRL (up to 13 weeks
6 days) and biparietal diameter thereafter. Fetal anthropometrics (HC, FL, and AC) were col-
lected from 12 weeks (HC and FL) and 16 or 18 weeks (AC) of gestation and measured to the
nearest millimetre using standard ultrasound planes [22]. From these measurements, fetal
Maternal smoking during pregnancy and fetal growth
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weight was estimated using the Hadlock 1985 formula [23]:
log
10
EFW ¼ 1:326   0:00326AC� FLþ 0:0107HCþ 0:0438ACþ 0:158FL
Anthropometric measurements at birth (HC and weight in both cohorts and AC in BiB
only) were obtained from obstetric medical records and combined with fetal anthropometric
data to estimate trajectories of fetal growth. In both cohorts, the median number of repeat
weight estimates per singleton was 3.
Other variables
The following variables were considered as potential confounders in multivariable analyses,
including for partner smoking associations: age, parity (at the time of index pregnancy; moth-
ers only), height, body mass index, education, and alcohol intake. In both cohorts, these vari-
ables were mainly derived from the baseline questionnaire administered at enrolment at a
median gestational age of 13 weeks (GenR) or 26 weeks (BiB). Full details of their assessment
and inclusion in the analysis models are provided in S1 Text.
Statistical analysis
A draft analysis plan was written by JSB, KT, and DAL in December 2017, and the final analy-
sis plan was agreed upon by all investigators in February 2018 after discussions with the GenR
team (see S2 Text). Analyses commenced in June 2018, and 2 changes were made after analyses
had begun. Preliminary results showed that maternal rs1051730 genotype was associated with
maternal age, and we decided to explore the impact of this by repeating all MR analyses with
adjustment for maternal age. In January 2019, in response to suggestions from one of the co-
authors, it was agreed that we would also estimate and report proportional differences in mean
fetal size as we might expect absolute differences to increase as the fetus grows. No further
changes to the analysis plan were made.
Fetal growth trajectories were derived using multilevel fractional polynomial models with 2
levels (i.e., measurements within occasions [level 1] within individuals [level 2]) as described
in detail elsewhere [21]. A variable for cohort (GenR versus BiB) and one for its interaction
with gestational age were entered in all models to account for between-study differences in
fetal growth. In pooling the data in a single analysis model, we assume that both cohorts are
from the same underlying population for which inferences can be made. To test this assump-
tion, we compared estimates obtained from this single analysis model with those observed in
GenR and BiB separately and further tested for between-study heterogeneity by adding a
3-way interaction term (between study, smoking exposure, and gestational age) to each analy-
sis model. More details on model specification can be found in S1 Text, including supportive
data for the growth trajectories fitted (S2 and S3 Tables; S2 Fig). We also compared the fetal
growth results with associations observed for birth weight using linear regression. Because
fetal growth trajectories, by definition, are conditioned on gestational age, we checked the
extent to which birth weight differences changed with adjustment for gestational age.
Multivariable and parental negative control analyses
Associations of maternal and partner smoking exposures were analysed by adding these vari-
ables as main effects and as interactions with gestational age to the multilevel models. From
these models, global p-values for these coefficients were derived to assess overall differences in
fetal growth (i.e., to test the null hypothesis that the growth trajectories across pregnancy for
different parameters do not differ, for example comparing smokers to non-smokers). This
Maternal smoking during pregnancy and fetal growth
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global approach is recommended to avoid multiple testing. Differences in mean fetal size asso-
ciated with each smoking exposure were estimated at 4-week intervals from 12–16 weeks
onwards in absolute original units (i.e., millimetres and grams) and proportionally as the ratio
of the observed differences to the mean at each time point. To provide an estimate of the tim-
ing of fetal growth restriction, we also report the earliest gestational age (based on 4-week
intervals) at which the 95% CI for a difference in mean fetal size did not include 0. It should,
however, be noted that this estimate is conservative as it is guided by statistical significance
only, and the actual process of growth restriction will have started prior to this point in time.
Fetal size differences by parental (maternal/partner) smoking status were estimated using
maternal/partner non-smokers as the reference group. Associations with parental smoking are
presented with adjustment for cohort only (model 1) and with adjustment for cohort, infant
sex, parity (for maternal smoking only), and respective parental age, height, BMI, education
level, and alcohol use during pregnancy (model 2). In the parental negative control compari-
son, associations were additionally mutually adjusted for the smoking behaviour of the other
parent (model 3).
Missing covariate data were imputed using multiple imputation stratified by cohort (see
details in S1 Text), and we also present results based on complete case data.
MR analysis
Fetal size differences by maternal rs1051730 genotype were modelled per risk allele (T)
increase (i.e., assuming an additive genetic effect). As rs1051730 genotype has been associated
with smoking quantity in individuals who smoke (with each T allele increase corresponding to
approximately 1 additional cigarette per day [17,24]), we would anticipate an association in
women continuing to smoke during pregnancy, and would expect this association to be
weaker in those who quit smoking and null in non-smokers. An association with fetal growth
in non-smokers would be indicative of a horizontal pleiotropic effect of the variant (i.e., not
acting through smoking intensity or inability to quit smoking) and would suggest that our
results in smokers may be biased [25]. In our main analyses we compared the associations of
the genetic variant with fetal growth in these 3 groups (pre-pregnancy smokers who continued
smoking through pregnancy, pre-pregnancy smokers who quit in early pregnancy, and non-
smokers). Stratifying pre-pregnancy smokers into those quitting and continuing smoking
could, however, introduce collider bias [26], as the rs1051730 T allele has previously been asso-
ciated with the ability to quit smoking [19]. We therefore repeated the MR analysis in just 2
groups: pre-pregnancy smokers and non-smokers. We examined associations of maternal
rs1051730 genotype with potential confounders of the smoking–fetal growth association to
test the independence assumption. To address the possibility of an association of maternal
rs1051730 being mediated through inheritance rather than a causal intrauterine effect, we per-
formed a sensitivity analysis with adjustment for fetal rs1051730 genotype. Fetal genotype data
were available for 4,457 singletons.
All analyses were undertaken using MLwiN version 2.4 run in Stata/MP version 15.
Results
Participant characteristics
Distributions of characteristics of participants included in the MR and negative control analy-
ses were very similar to those included in the main analysis of maternal smoking effects (S4
Table). In GenR, 1,221 women (26%) reported smoking prior to pregnancy, including 423
who quit early in pregnancy (9%) and 798 (17%) who continued smoking through pregnancy.
Corresponding percentages of pre-pregnancy smoking (41%) and continued smoking (30%)
Maternal smoking during pregnancy and fetal growth
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were higher in BiB, whereas the proportion of women quitting in early pregnancy was similar
to that observed in GenR (11%) (Table 1). Overall, 44% and 35% of partners smoked in GenR
and BiB, respectively. In both cohorts, mothers who continued smoking during pregnancy
were younger, shorter, less educated, and more often multiparous, and gave birth to infants of
lower gestational age and birth weight (S5 Table). In BiB, mothers who continued smoking
also had a lower BMI (S5 Table). Similar associations with these characteristics were observed
for partner smoking status during pregnancy (S6 Table).
Associations of maternal smoking with fetal growth
Differences in mean fetal size across gestation by maternal smoking during pregnancy are pre-
sented in Fig 1, with estimates from multivariable adjusted analyses shown in S7 Table. Over-
all, trajectories of fetal growth varied according to maternal smoking status (p< 0.001 for each
fetal parameter). From the early second trimester through to term, fetuses of women who con-
tinued to smoke weighed less than those of non-smokers. More specifically, at 20 weeks, the
predicted difference (95% CI) in mean EFW was −2.6 g (−5.1 to −0.1), and this absolute differ-
ence increased to −207 g (−231 to −182) at 40 weeks’ gestation. A similar pattern was observed
Table 1. Participant characteristics of the study population stratified by cohort.
Characteristic GenR
(n = 4,682)
BiB
(n = 3,939)
Maternal age, years, mean (SD) 31.3 (4.6) 26.7 (6.0)
Smoking during pregnancy, percent (n)
Non-smoker 73.9 (3,461) 59.1 (2,328)
Pre-pregnancy smoker who quit before the second trimester 9.0 (423) 10.8 (427)
Pre-pregnancy smoker who continued through pregnancy 17.0 (798) 30.1 (1,184)
Smoking intensity in pre-pregnancy smokers who continued through pregnancy,
percent (n)
Light 40.3 (309) 71.5 (2,328)
Moderate 38.5 (295) 19.0 (618)
Heavy 21.3 (163) 9.5 (309)
Missing 3.9 (31) 0 (0)
Partner smoking during pregnancy, percent (n)
No 56.4 (2,373) 64.8 (862)
Yes 43.6 (1,833) 35.2 (469)
Missing 10.2 (476) 66.2 (2,608)
Smoking intensity in partner’s smoking during pregnancy, percent (n)
Light 35.1 (633) 18.3 (84)
Moderate 16.8 (303) 37.4 (172)
Heavy 48.1 (868) 44.3 (204)
Missing 1.6 (29) 1.9 (9)
Maternal rs1051730 genotype (number of T alleles), percent (n)
0 45.3 (1,633) 45.7 (1,337)
1 43.0 (1,551) 43.7 (1,277)
2 11.7 (420) 10.6 (309)
Missing 23.0 (1,078) 25.8 (1,016)
For all smoking variables, percentages (n) of each category are given only for singleton births with no missing values,
to facilitate comparison between the 2 cohorts.
BiB, Born in Bradford study; GenR, Generation R Study.
https://doi.org/10.1371/journal.pmed.1002972.t001
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for HC, FL, and AC, with absolute differences in each fetal parameter widening with gesta-
tional age. Fetal FL reductions were observed from 16 weeks, and fetal HC and AC reductions
were observed from 20 and 24 weeks, respectively. The EFW trajectory of women who quit
smoking early in pregnancy was similar to that of non-smokers (Fig 1; S7 Table). However,
quitters had a shorter FL and greater AC than non-smokers towards the end of pregnancy,
though these differences were smaller in magnitude than those observed for continuing
smokers.
Fetal size differences by smoking quantity in mothers who continued smoking during preg-
nancy are shown in Fig 2 and S8 Table. Dose–response associations with EFW and individual
fetal parameters (HC, FL, and AC) were observed from early gestation through to birth
(p< 0.001 for all fetal parameters). Compared to non-smokers, the difference (95% CI) in
mean EFW for light, moderate, and heavy smoking in women who continued smoking was
−144 g (−182 to −106), −215 g (−248 to −182), and −290 g (−334 to −247) at 40 weeks, respec-
tively. As was the case for smoking status, associations of smoking quantity with fetal parame-
ters appeared to be most pronounced for FL. Results for predicted differences as a proportion
of the mean revealed a similar pattern as for mean differences in absolute original units: pro-
portional differences in fetal parameters observed with maternal smoking status and smoking
quantity followed an increasing pattern with increasing gestational age (S9 and S10 Tables).
Fig 1. Predicted differences in mean fetal size (with 95% CIs) across gestation comparing pre-pregnancy smokers
who quit early in pregnancy and pre-pregnancy smokers who continued smoking through pregnancy with non-
smokers (reference category). Predicted differences in mean head circumference (mm), femur length (mm),
abdominal circumference (mm), and estimated fetal weight (g) across gestation comparing pre-pregnancy smokers
who quit in early pregnancy and those who continued smoking during pregnancy with non-smokers (reference
category). Predicted mean differences (with 95% confidence intervals) in the pooled Generation R Study and Born in
Bradford study cohort by analysis model: model 1 adjusting for cohort only (in white) and model 2 adjusting for
cohort, infant sex, and maternal age, parity, height, body mass index, education level, and alcohol use during
pregnancy (in black).
https://doi.org/10.1371/journal.pmed.1002972.g001
Maternal smoking during pregnancy and fetal growth
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Association of maternal rs1051730 genotype with smoking and fetal
growth—MR analysis
Maternal rs1051730 genotype was associated with the ability to quit smoking among pre-preg-
nancy smokers (per T allele odds ratio [OR] for continuing versus quitting smoking during
pregnancy = 1.10 [95% CI 0.96 to 1.25]). This association was mainly driven by GenR
(OR = 1.17 [95% CI 0.96 to 1.43]) as rs1051730 was not clearly associated with the ability to
quit smoking in BiB (OR = 1.03 [95% CI 0.86 to 1.24]) (S11 Table). In both cohorts, maternal
rs1051730 genotype was associated with the number of cigarettes smoked in women who con-
tinued smoking during pregnancy (per T allele OR for heavy smoking versus light/moderate
smoking = 1.24 [95% CI 1.04 to 1.47]), but not in those who quit smoking in early pregnancy
(OR = 1.02 [95% CI 0.79 to 1.33]). The SNP was not associated with being a smoker (per T
allele OR for being a pre-pregnancy smoker = 1.00 [95% CI 0.92 to 1.08]), confirming
genome-wide association results that rs1051730 is not associated with smoking initiation [18].
Associations of maternal rs1051730 genotype with fetal growth differed by smoking status
(Fig 3; S12 Table). Amongst women who continued to smoke across pregnancy, EFW growth
differed by rs1051730 genotype (p = 0.01). At 20 weeks’ gestation, each additional T allele was
associated with a lower EFW (−3.7 g [95% CI −7.0 to −0.4]), and this absolute reduction in
fetal weight increased in magnitude with gestational age (at 40 weeks it was −45 g [95% CI −81
to −10]). A similar pattern of fetal growth restriction was observed for individual fetal
Fig 2. Predicted differences in mean fetal size (with 95% CIs) across gestation comparing different categories of smoking quantity in pre-
pregnancy smokers who continued smoking through pregnancy with non-smokers (reference category). Predicted differences in mean head
circumference (mm), femur length (mm), abdominal circumference (mm), and estimated fetal weight (g) across gestation comparing pre-pregnancy
smokers who continued smoking through pregnancy by smoking intensity with non-smokers (reference category). Predicted mean differences (with
95% confidence intervals) in the pooled Generation R Study and Born in Bradford study cohort by analysis model: model 1 adjusting for cohort only
(in white) and model 2 adjusting for cohort, infant sex, and maternal age, parity, height, body mass index, education level, and alcohol use during
pregnancy (in black).
https://doi.org/10.1371/journal.pmed.1002972.g002
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parameters (HC, FL, and AC) in these women, though differences in mean fetal AC were less
precise and close to null in late gestation. In women classified as non-smokers, each additional
T allele at rs1051730 was associated with a higher EFW between 32 weeks and 40 weeks of ges-
tation (p for overall difference in growth = 0.03), with similar patterns of associations for HC,
AC, and FL. No association between maternal rs1051730 genotype and fetal growth was
observed in women who quit smoking in early pregnancy, but these results need to be inter-
preted with caution because of the small number of individuals in this group. Proportional dif-
ferences in mean fetal size with each additional T allele at rs1051730 followed a similar pattern
as for the absolute differences observed (S13 Table). Effect estimates were not materially differ-
ent after combining pre-pregnancy smokers who quit and those who continued smoking (S14
Table; S3 Fig). With the exception of maternal age, the SNP was not associated with confound-
ers (S15 Table). Maternal age in continuing smokers increased with each additional T allele;
there was no association with age in non-smokers and those who quit smoking in early preg-
nancy. Results were not altered with adjustment for maternal age (S4 and S5 Figs) or fetal
rs1051730 genotype (Figs 3 and S3–S5).
Association of maternal versus mother’s partner smoking with fetal
growth—Parental negative control analysis
In unadjusted analyses, partner smoking was associated with slower growth of all parameters
(S6 Fig), but these associations were considerably weaker than those for maternal smoking and
were only apparent later in pregnancy (from 32 weeks onwards). The partner smoking
Fig 3. Predicted differences in mean fetal size (with 95% CIs) across gestation per risk allele increase at rs1051730 in non-smokers, pre-
pregnancy smokers who quit early in pregnancy, and pre-pregnancy smokers who continued smoking through pregnancy. Predicted differences in
mean head circumference (mm), femur length (mm), abdominal circumference (mm), and estimated fetal weight (g) per maternal rs1051730 T allele
increase in non-smokers, pre-pregnancy smokers who quit smoking in early pregnancy, and pre-pregnancy smokers who continued smoking during
pregnancy. Predicted mean differences (with 95% confidence intervals) by analysis model: model 1 adjusting for cohort (in white) and model 2
adjusting for cohort and fetal rs1051730 genotype (in black).
https://doi.org/10.1371/journal.pmed.1002972.g003
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associations were attenuated to the null after multivariable adjustment for confounders and
mutual adjustment for maternal smoking (Figs 4 and S6; S16 and S17 Tables). Results for part-
ner smoking quantity showed similar patterns (S7 Fig).
Additional analyses
Effect estimates of the association between mother’s and mother’s partner’s smoking status
during pregnancy with fetal growth were not materially different in analyses restricted to those
with complete covariate data (S8–S12 Figs). Associations were very similar in GenR and BiB,
with no statistical evidence for any differences between the 2 cohorts (pinteraction > 0.05 for all
analysis models; S7–S10 and S12–S17 Tables). Also, associations of maternal smoking with
birth weight were consistent in direction and effect size with the fetal size differences observed
during late gestation, and conditioning on gestational age did not strongly influence these
associations (S18 Table).
Discussion
In this study we found that infants of pre-pregnancy smokers who continued smoking during
pregnancy had a reduced fetal size from early second trimester to term, and that this
Fig 4. Predicted differences in mean fetal size (with 95% CIs) across gestation comparing mothers and mother’s
partners who smoked to non-smokers (reference category). Predicted differences in mean head circumference
(mm), femur length (mm), abdominal circumference (mm), and estimated fetal weight (g) across gestation associated
with maternal smoking (i.e., comparing maternal continued smoking through pregnancy with no maternal smoking
during pregnancy [reference category]) and mother’s partner’s smoking (comparing partner smoking during
pregnancy with no partner smoking during pregnancy [reference category]). Predicted mean differences associated
with maternal smoking (in white) and partner smoking (in black) are adjusted for cohort, infant sex, parity (for
maternal smoking only), and respective parental age, height, BMI, education level, and alcohol use during pregnancy,
and mutually adjusted for the smoking behaviour of the other parent.
https://doi.org/10.1371/journal.pmed.1002972.g004
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association followed a dose-dependent pattern (with reductions in fetal size being present in
light smokers but of lower magnitude than in moderate or heavy smokers) and was indepen-
dent of observed confounding factors. Furthermore, the lack of an equivalent association for
partner’s smoking with fetal growth and the results from MR, which showed evidence of a lin-
ear association of increasing cigarette consumption with fetal growth restriction, provide sup-
port that these associations represent an intrauterine effect and are not explained by
unmeasured residual confounding factors. Pre-pregnancy smokers who gave up smoking
before the second trimester had broadly similar fetal growth to non-smokers except for a
shorter FL and greater AC between 36 and 40 weeks of gestation.
Strengths and limitations
A strength of our study is the large population-based sample with detailed information on
smoking (including dose–response data) and on potential confounders. We triangulated evi-
dence from conventional multivariable regression analyses in mothers with evidence from
parental negative control and genetic MR analyses. The consistent findings across these 3
methods—which have differing key sources of bias (residual confounding in the multivariable
analyses, unanticipated causal effect of partner smoking in the negative control, and genetic
horizontal pleiotropy in MR)—strengthen confidence in our conclusions [13]. Multiple sensi-
tivity analyses suggested that the multivariable regression analyses were not biased by selection
due to missing covariate data, and that stratified genetic analyses were not notably influenced
by collider bias. An assumption of MR analysis is that the genetic instrument influences the
outcome only through the exposure of interest. One theoretical source of violation of this
assumption is via fetal genotype, but we found no difference in the maternal SNP–fetal growth
associations with adjustment for fetal genotype. The positive association of maternal
rs1051730 genotype with EFW between 32 and 40 weeks of gestation in non-smokers suggests
that genetic pleiotropy may have resulted in violation of the assumption that the genetic instru-
ment influences fetal growth only via maternal smoking. Previous MR studies using the
rs1051730 genotype have demonstrated that smoking is causally related to a lower BMI in
smokers and higher BMI, and waist and hip circumference, in non-smokers [27,28]. This
raises the possibility that the association of the variant with offspring EFW in non-smokers is
mediated through an increase in maternal body mass and that in smokers associations may be
stronger (i.e., there may have been some masking of the association by a pleiotropic path
through maternal BMI). Our MR results are consistent with those from a large study of 26,241
mother–infant pairs, which found a negative association of rs1051730 with birth weight in
smokers but no strong evidence of an association in non-smokers (difference in mean birth
weight per T allele = 5 g [95% CI −4 to 14]) [8].
The parental negative control study assumes that factors related to maternal smoking are
similar to those related to their partner’s smoking (i.e., that confounding is the same for the
‘real’ and ‘negative control’ exposure), which is plausible given that risk factors for smoking,
such as low socioeconomic position, have not been shown to be sex-specific. This approach
also assumes that it is not plausible that the negative control influences the outcome. Whilst
partner smoking, and that of others whom the mother is exposed to, could have an intrauter-
ine effect via passive smoking, we would expect this effect to be considerably smaller than what
is seen with maternal smoking. The fact that we see in our analyses presented here a maternal-
specific association with fetal growth parameters, as has been shown for birth weight [9], sup-
ports an intrauterine mechanism that is not explained by shared familial confounding.
In both GenR and BiB, pregnancies were dated using fetal biometry using CRL and biparie-
tal diameter. Although this approach is superior to the use of women’s self-report of last
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menstrual period, it assumes no variation in fetal size at the time of dating, which may have
led to an underestimation of smoking associations. Moreover, as there is some evidence of
maternal smoking being associated with reduced first trimester CRL [11], systematic underes-
timation of gestational age in women who smoke during pregnancy could have further limited
our ability to detect (stronger) associations. Since we modelled longitudinal fetal growth, and
since ultrasound fetal anthropometrics tend to correlate less with dating measures as pregnancy
progresses, we expect this to have resulted in an underestimation of fetal size differences only
during early gestation. We further note that associations of maternal smoking with fetal AC
attenuated towards term, most likely because of limited power as AC was not measured at birth
in GenR. Information about smoking during pregnancy was collected by questionnaire. Several
studies using cotinine as a biochemical measure of smoking exposure have demonstrated
underreporting of smoking among pregnant women [29,30]. It is therefore likely that not all
women in our study admitted smoking and when reporting smoking may have systematically
underestimated the number of cigarettes smoked or falsely reported having quit. In the multi-
variable regression analyses, this misreporting could have resulted in associations with whether
mothers smoked or not being biased towards the null, and associations with light/moderate
smoking and smoking cessation being biased away from the null. In MR analyses, this misclassi-
fication would be expected to potentially bias results for non-smokers and quitters towards the
results for smokers (i.e., as the group of non-smokers and quitters may have included some
smokers), but not to bias causal effect estimates for smoking quantity within smokers.
Partners can be difficult to recruit to pregnancy cohorts, and data on behaviours like smok-
ing is sometimes collected from the pregnant woman (as was the case for most partners in
GenR) or there is a smaller proportion of partners with data (as was the case for BiB) [31]. The
fact that we found consistent results for partner smoking in GenR, where information on part-
ner smoking was based predominantly on maternal report (which may be biased towards the
maternal association), and BiB, in which only a small proportion of partners responded
(where there may be selection bias), suggests that the null findings for partner smoking are
robust. Finally, as this study included women of white European origin only, results may not
necessarily generalise to other populations.
Comparison with other studies
Our results are consistent with those from a systematic review, which reported lower third tri-
mester fetal size and second trimester reductions in some fetal parameters in women who con-
tinued smoking during pregnancy [12]. That review, however, could not assess fetal growth
trajectories across pregnancy from early gestation to term, or explore dose-dependent patterns
or the impact of quitting in detail, and it did not include methods we used to explore causality.
Our MR estimates of EFW reductions of 37 g (95% CI 14 to 60) and 45 g (95% CI 10 to 81) per
genetically determined 1-cigarette-per-day increase at 36 and 40 weeks’ gestation in women
who continued smoking beyond the first trimester are broadly consistent with the 24-g (95%
CI 3 to 45) reduction in birth weight reported in a previous MR analysis [8]. Our genetic
results are also comparable with those from a randomized smoking cessation trial showing a
reduction of approximately 5.4 cigarettes per day and a 92-g heavier birth weight in the inter-
vention compared to the control group (giving an average increase of 17.9 g per 1 less ciga-
rette) [5]. Of note, rs1051730 genotype is an instrument for both smoking quantity (in current
smokers, i.e., pre-pregnancy smokers who continue smoking during pregnancy) and smoking
cessation (in pre-pregnancy smokers), 2 independent traits that are strongly correlated. As we
found similar associations in analyses including all pre-pregnancy smokers, our results support
the importance of smoking reduction and cessation to prevent fetal growth restriction. The
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absence of an independent association of mother’s partner’s smoking with fetal growth pro-
vides additional support for maternal smoking influencing early fetal growth through an intra-
uterine mechanism and is consistent with a previous negative control study investigating
parental smoking associations with birth weight [9].
Different fetal parameters have different peak periods of growth during gestation as reflected
by the shapes of their growth trajectories, i.e., linear growth of HC and FL is highest during
early pregnancy and starts to level off at approximately 20 weeks of gestation, while the peak
growth of AC is observed between approximately 20 and 32 weeks (reflecting the predominant
accumulation of fat and lean tissue during the third trimester) [32]. These differences in fetal
growth patterns may affect the timing at which associations with each fetal parameter can be
observed. Differences in smoking effects on fetal growth parameters may also reflect develop-
mental plasticity and the ‘protection’ of some organs and tissues over others. In our study, asso-
ciations of maternal smoking with fetal growth were first noted for FL, with differences in FL
being detectable from as early as 16 weeks’ gestation. Compared to non-smokers, pre-pregnancy
smokers who quit smoking before the second trimester had a shorter fetal FL at 36–40 weeks’
gestation, whereas no differences in size were observed for other growth parameters. If the toxic
effects of smoking affected the growth of different tissues and organs similarly and the main
cause of differences between them was related to timing of peak growth, we would have
expected similar patterns between FL and HC, which is not what we find.
A predominant association of maternal smoking with FL has been reported before by other
studies including GenR [20,33–35] and animal experiments [36], and for many years, leg length
has been proposed to be the most sensitive growth parameter to adverse early-life exposures
[37]. A Swedish register-based study found that infants of women who quit smoking during
pregnancy had a similar birth weight and HC to infants of non-smokers, but a shorter crown–
heel length [38]. Since birth crown–heel length is a measure of linear growth that is closely cor-
related to FL [39], these data are consistent with our findings. Taking our findings together with
those from human and animal experimental studies, it appears that fetal skeletal linear growth
is particularly susceptible to maternal cigarette smoking. It seems plausible that in the presence
of reduced nutrient and oxygen supply to the fetus, as a result of smoking [40], key organs, such
as the brain and liver, are preserved as much as possible at the expense of skeletal growth. We
further observed a greater fetal AC towards the end of gestation in women who quit smoking
early in pregnancy compared to non-smokers. Smoking cessation is often accompanied by
weight gain and changes in central fat tissue [41,42], most likely through an increased appetite
and lower basal metabolic rate upon nicotine withdrawal. This could potentially explain the
larger fetal AC found among quitters, but because of the small number of quitters in this study,
we were unable to explore the causal nature of this association further in MR analysis.
Implications
Harmful effects of maternal smoking during pregnancy are well known. However, many
women who smoke find it difficult to quit before or during pregnancy [43], as evidenced by
the relatively high rates of smoking prior to pregnancy (26% and 41%) and low quit rates in
early pregnancy (35% and 27% of pre-pregnancy smokers) in the 2 contemporary cohorts of
white European women in our study. Our study is the first to our knowledge to provide robust
support for an association between the number of cigarettes smoked and fetal size from as
early as 20 weeks’ gestation in women who continue smoking after the first trimester. There
are 2 key implications of these findings. First, even at low doses, cigarette smoking adversely
affects fetal growth, and continued efforts to prevent women of reproductive age from smok-
ing, and to support those who do take it up to quit, are paramount. In this context, our findings
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reinforce existing recommendations [44–46] that encourage strategies to reduce initiation,
improve detection, and promote cessation of tobacco use including cessation counselling as
part of preconception health services and antenatal care. Simultaneously, the absence of major
fetal growth deficits observed with smoking cessation early in pregnancy should comfort
women with unplanned pregnancies who are able to quit smoking early after realising they are
pregnant, but who may have experienced anxiety because of smoking in that early period of
pregnancy. Second, for women who do not manage to quit smoking before or during preg-
nancy, smoking reduction will have some benefit in a linear fashion, i.e., the greater the reduc-
tion in smoking, the smaller the likelihood of fetal growth restriction; therefore, support to
lower the number of cigarettes smoked in these women should be promoted. Currently, few
guidelines suggest this, perhaps because of fear that it may be interpreted as condoning light
smoking in pregnancy. We believe our results provide sufficient evidence to update guidelines
that currently promote only quitting, not reducing, smoking: For women who find it too diffi-
cult to quit smoking before or during pregnancy, support to reduce the amount they smoke
should be provided. We acknowledge that fetal growth restriction, despite being a predictor of
neonatal morbidity and mortality, is only one of the adverse outcomes associated with preg-
nancy smoking, and it is unknown whether lowering cigarette consumption in those who can-
not quit will be beneficial for other perinatal outcomes. Finally, our findings should stimulate
more research to further explore the effectiveness and safety of currently available interven-
tions that might reduce smoking in pregnancy [47]. The potential effect of electronic cigarettes
and other smokeless tobacco products, which women may use as a means to quit smoking or
as potentially safer alternatives to cigarette smoking, on fetal growth and perinatal outcomes
requires investigation. However, as these alternatives have only recently become available, we
did not have information on their use in either of these cohorts, and it will take some time
before other cohorts with sufficient information on these will be available for analyses.
Conclusions
By triangulating findings from different analytical approaches, this study provides strong sup-
port for a dose-dependent effect of cigarette smoking on fetal growth from the second trimes-
ter onwards in women who continue smoking during pregnancy, while only minor deficits in
fetal growth are seen in women who quit smoking early in pregnancy. Collectively, these find-
ings reinforce the importance of smoking cessation counselling in preconception health ser-
vices and antenatal care. They demonstrate the importance of quitting smoking early in
pregnancy, which is knowledge that could also help reduce anxiety in women who quit after
learning they are pregnant. Lastly, our findings indicate that support and advice to reduce
smoking during pregnancy in women who find it impossible to quit has some benefit in lower-
ing the risk of fetal growth restriction.
Supporting information
S1 Fig. Flow chart of the study population.
(TIF)
S2 Fig. Best-fitting growth trajectories for each fetal parameter identified by multilevel
fractional polynomial models in GenR and BiB. Average growth trajectories of fetal HC, FL,
AC, and EFW from 12–16 to 40 weeks’ gestation predicted by best-fitting multilevel fractional
polynomial models in GenR and BiB.
(TIF)
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S3 Fig. Predicted differences in mean fetal size (with 95% CIs) across gestation per risk
allele increase at rs1051730 in pre-pregnancy smokers and non-smokers. Predicted differ-
ences in mean HC (mm), FL (mm), AC (mm), and EFW (g) across gestation per maternal
rs1051730 T allele increase in pre-pregnancy smokers and non-smokers. Predicted mean dif-
ferences (with 95% confidence intervals) in the pooled GenR and BiB cohort by analysis
model: model 1 adjusting for cohort (in white) and model 2 adjusting for cohort and fetal
rs1051730 genotype (in black).
(TIF)
S4 Fig. Predicted differences in mean fetal size (with 95% CIs) across gestation per risk
allele increase at rs1051730 in non-smokers, pre-pregnancy smokers who quit in early
pregnancy, and pre-pregnancy smokers who continued smoking during pregnancy—Anal-
ysis with adjustment for maternal age. Predicted differences in mean HC (mm), FL (mm),
AC (mm), and EFW (g) across gestation per maternal rs1051730 T allele increase in non-
smokers, pre-pregnancy smokers who quit smoking before the second trimester, and pre-preg-
nancy smokers who continued smoking during pregnancy. Predicted mean differences (with
95% confidence intervals) in the pooled GenR and BiB cohort by analysis model: model 1
adjusting for cohort and maternal age (in white) and model 2 adjusting for cohort, maternal
age, and fetal rs1051730 genotype (in black).
(TIF)
S5 Fig. Predicted differences in mean fetal size (with 95% CIs) across gestation per risk
allele increase at rs1051730 in pre-pregnancy smokers and non-smokers—Analysis with
adjustment for maternal age. Predicted differences in mean HC (mm), FL (mm), AC (mm),
and EFW (g) across gestation per maternal rs1051730 T allele increase in pre-pregnancy smok-
ers and non-smokers. Predicted mean differences (with 95% confidence intervals) in the
pooled GenR and BiB cohort by analysis model: model 1 adjusting for cohort and maternal
age (in white) and model 2 adjusting for cohort, maternal age, and fetal rs1051730 genotype
(in black).
(TIF)
S6 Fig. Predicted differences in mean fetal size (with 95% CIs) across gestation comparing
mothers’ partners who smoked with non-smoking partners (reference category). Predicted
differences in mean HC (mm), FL (mm), AC (mm), and EFW (g) across gestation comparing
partners who smoked during pregnancy to those who did not smoke during pregnancy (refer-
ence category). Predicted mean differences (with 95% confidence intervals) in the pooled
GenR and BiB cohort by analysis model: model 1 adjusting for cohort only (in white); model 2
adjusting for cohort, infant sex, and partner age, height, body mass index, education level, and
alcohol use during pregnancy (in grey); and model 3 adjusting for cohort; infant sex; partner
age, height, body mass index, education level, and alcohol use during pregnancy; and smoking
during pregnancy (in black).
(TIF)
S7 Fig. Predicted differences in mean fetal size (with 95% CIs) across gestation comparing
different categories of smoking intensity in mothers’ partners who smoked with non-
smoking partners (reference category). Predicted differences in mean HC (mm), FL (mm),
AC (mm), and EFW (g) across gestation comparing partners who smoked during pregnancy
by smoking intensity with those who did not smoke during pregnancy (reference category).
Predicted mean differences (with 95% confidence intervals) in the pooled GenR and BiB
cohort by analysis model: model 1 adjusting for cohort only (in white); model 2 adjusting for
cohort, infant sex, and partner age, height, body mass index, education level, and alcohol use
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during pregnancy (in grey); and model 3 adjusting for cohort; infant sex; partner age, height,
body mass index, education level, and alcohol use during pregnancy; and maternal smoking
during pregnancy (in black).
(TIF)
S8 Fig. Predicted differences in mean fetal size (with 95% CIs) across gestation comparing
pre-pregnancy smokers who quit in early pregnancy and pre-pregnancy smokers who con-
tinued smoking through pregnancy with non-smokers (reference category)—Complete
case analysis. Predicted differences in mean HC (mm), FL (mm), AC (mm), and EFW (g)
across gestation comparing pre-pregnancy smokers who quit smoking in early pregnancy and
those who continued smoking during pregnancy with non-smokers (reference category)—
complete case analysis. Predicted mean differences (with 95% confidence intervals) in the
pooled GenR and BiB cohort by analysis model: model 1 adjusting for cohort only (in white)
and model 2 adjusting for cohort, infant sex, and maternal age, parity, height, body mass
index, education level, and alcohol use during pregnancy (in black).
(TIF)
S9 Fig. Predicted differences in mean fetal size (with 95% CIs) across gestation comparing dif-
ferent categories of smoking intensity in pre-pregnancy smokers who continued smoking
through pregnancy with non-smokers (reference category)—Complete case analysis. Predicted
differences in mean HC (mm), FL (mm), AC (mm), and EFW (g) across gestation comparing
pre-pregnancy smokers who continued smoking through pregnancy by smoking intensity with
non-smokers (reference category)—complete case analysis. Predicted mean differences (with 95%
confidence intervals) in the pooled GenR and BiB cohort by analysis model: model 1 adjusting for
cohort only (in white) and model 2 adjusting for cohort, infant sex, and maternal age, parity,
height, body mass index, education level, and alcohol use during pregnancy (in black).
(TIF)
S10 Fig. Predicted differences in mean fetal size (with 95% CIs) across gestation comparing
mothers’ partners who smoked with non-smoking partners (reference category)—Complete
case analysis. Predicted differences in mean HC (mm), FL (mm), AC (mm), and EFW (g)
across gestation comparing partners who smoked during pregnancy with those who did not
smoke during pregnancy (reference category)—complete case analysis. Predicted mean differ-
ences (with 95% confidence intervals) in the pooled GenR and BiB cohort by analysis model:
model 1 adjusting for cohort only (in white); model 2 adjusting for cohort, infant sex, and part-
ner age, height, body mass index, education level, and alcohol use during pregnancy (in grey);
and model 3 adjusting for cohort; infant sex; partner age, height, body mass index, education
level, and alcohol use during pregnancy; and maternal smoking during pregnancy (in black).
(TIF)
S11 Fig. Predicted differences in mean fetal size (with 95% CIs) across gestation comparing
different categories of smoking intensity in mothers’ partners who smoked with non-
smoking partners (reference category)—Complete case analysis. Predicted differences in
mean HC (mm), FL (mm), AC (mm), and EFW (g) across gestation comparing partners who
smoked during pregnancy by smoking intensity with those who did not smoke during preg-
nancy (reference category)—complete case analysis. Predicted mean differences (with 95%
confidence intervals) in the pooled GenR and BiB cohort by analysis model: model 1 adjusting
for cohort only (in white); model 2 adjusting for cohort, infant sex, and partner age, height,
body mass index, education level, and alcohol use during pregnancy (in grey); and model 3
adjusting for cohort; infant sex; partner age, height, body mass index, education level, and
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alcohol use during pregnancy; and maternal smoking during pregnancy (in black).
(TIF)
S12 Fig. Predicted differences in mean fetal size (with 95% CIs) across gestation comparing
mothers and mothers’ partners who smoked to non-smokers (reference category)—Com-
plete case analysis. Predicted differences in mean HC (mm), FL (mm), AC (mm), and EFW
(g) across gestation associated with maternal smoking (i.e., comparing maternal continued
smoking through pregnancy with no maternal smoking during pregnancy [reference cate-
gory]) and mother’s partner’s smoking (comparing partner smoking during pregnancy with
no partner smoking during pregnancy [reference category])—complete case analysis. Pre-
dicted mean differences associated with maternal smoking (in white) and partner smoking (in
black) are adjusted for cohort, infant sex, parity (for maternal smoking only), and respective
parental age, height, BMI, education level, and alcohol use during pregnancy, and mutually
adjusted for the smoking behaviour of the other parent.
(TIF)
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